FO
SAGE

FT Options’s Sage Therapeutics SAGE Stock Holding History

FT Options’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$184K Sell
2,957
-6,873
-70% -$540K 0.28% 69
2017
Q2 		$783K Sell
9,830
-9,383
-49% -$678K 1.35% 21
2017
Q1 		$1.36M Buy
19,213
+3,235
+20% +$189K 1.8% 10
2016
Q4 		$816K Buy
15,978
+3,200
+25% +$151K 0.94% 27
2016
Q3 		$588K Buy
12,778
+4,005
+46% +$163K 0.47% 50
2016
Q2 		$264K Buy
+8,773
New +$293K 0.23% 82

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FT Options's SAGE Position: Q3 2017 in Review

FT Options reduced its Sage Therapeutics (SAGE) stake by 70% in Q3 2017, selling an estimated $540K and leaving 2,957 shares worth $184K. The position accounts for 0.28% of the portfolio, ranked #69.

FT Options first reported a position in SAGE in Q2 2016 and has held it in 6 quarters since. The position peaked at $1.36M in Q1 2017. 174 funds tracked by Wall St. Rank hold SAGE as of Q3 2017.

  • FT Options held 2,957 shares of Sage Therapeutics worth $184K as of Q3 2017.
  • FT Options sold 6,873 Sage Therapeutics shares in Q3 2017, an estimated $540K.
  • Sage Therapeutics made up 0.28% of FT Options's portfolio in Q3 2017, its #69 holding.
  • FT Options first reported a position in Sage Therapeutics in Q2 2016 and has held it in 6 quarters since.
  • FT Options's Sage Therapeutics position peaked at $1.36M in Q1 2017.
  • 174 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.